If you have been reading about HGF/c-Met and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Bacteria display a wide diversity of shapes and sizes. Bacterial cells are about one-tenth the size of eukaryotic cells and are typically 0.5–5.0 micrometres in length. However, a few species are visible to the unaided eye—for example, Thiomargarita namibiensis is up to half a millimetre long, Epulopiscium fishelsoni reaches 0.7 mm, and Thiomargarita magnifica can reach even 2 cm in length, which is 50 times larger than other known giant bacteria. Among the smallest bacteria are members of the genus Mycoplasma, which measure only 0.3 micrometres, as small as the largest viruses. Some bacteria may be even smaller, but these ultramicrobacteria are not well-studied.
The needle may cut small pieces of rubber from the septum as it injects sample through it. These can block the needle and prevent the syringe filling the next time it is used. It may not be obvious that this has happened. A fraction of the sample may get trapped in the rubber, to be released during subsequent injections. This can give rise to ghost peaks in the chromatogram. There may be selective loss of the more volatile components of the sample by evaporation from the tip of the needle.
=== United Kingdom === Beef Stroganoff began appearing in British cookery books in the early 1930s and became widely popular by the 1970s, particularly in restaurants and at dinner parties. The dish later declined in popularity and became associated with mass-produced ready meals and buffet-style catering. Modern British adaptations often include a creamy sauce made with white wine or brandy, sour cream or crème fraîche, and additions such as smoked paprika and English mustard. While beef fillet was traditionally used, contemporary recipes frequently use alternative proteins such as pork, chicken or sausages. The dish is commonly served with rice, tagliatelle, or potatoes. In recent years, it has experienced limited revival in British food media, pub cuisine, and home cooking.
=== 2000–present === In September 2002, Lilly partnered with Amylin Pharmaceuticals to develop and commercialize Amylin's new drug based on exendin-4, a novel substance isolated from the venom of the Gila monster. Exenatide, the first of the GLP-1 receptor agonists, was approved by the US Food and Drug Administration in April 2005. In 2003, Lilly introduced Cialis (tadalafil), a competitor to Viagra for erectile dysfunction developed in a partnership with Icos. Cialis maintains an active period of 36 hours, causing it sometimes to be dubbed the "weekend pill". It was advertised during the 2004 Super Bowl XXXVIII and 2005 Super Bowl XXXIX halftime shows. In 2004, Lilly introduced duloxetine (Cymbalta), a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder. It ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis. In January 2007, Lilly acquired Icos for $2.1 billion, after raising its offer and facing opposition from Institutional Shareholder Services. Lilly subsequently closed Icos' manufacturing operations, terminated nearly 500 Icos employees, leaving 127 employees working at the biologics facility. In December 2007, CMC Biopharmaceuticals A/S (CMC), a Copenhagen-based provider of contract biomanufacturing services, bought the Bothell, Washington-based biologics facility from Lilly and retained the existing 127 employees.
=== Phase 2 === Abatacept (Orencia) – injection – alopecia areata – T cell activation inhibitor Amlitelimab (KY-1005, SAR-445229) – subcutaneous injection – alopecia areata – OX40 ligand inhibitor BAY-1158061 (HMI-115) – subcutaneous injection – alopecia – prolactin receptor monoclonal antibody (prolactin receptor inhibitor) Bempikibart (ADX-914, BMS-986265) – subcutaneous injection – alopecia areata – CRLF2 protein antagonist, interleukin 7 receptor α subunit inhibitor Bimatoprost (Lumigan) – topical – alopecia – prostaglandin F receptor agonist (prostaglandin F2α analogue) Botulinum toxin A (Xeomin; incobotulinum toxin A) – intradermal – alopecia – acetylcholine release inhibitor and neuromuscular blocking agent CKD-498 – oral – alopecia – undefined mechanism of action Daxdilimab (HZN-7734; MEDI-7734; VIB-7734) – oral – alopecia areata – anti-ILT7 human monoclonal antibody/dendritic cell inhibitor Delgocitinib (Anzupgo, Corectim; JTE-052, LEO-124249, LP-0133) – unknown – alopecia areata – Janus kinase inhibitor Deucravacitinib (Sotyktu; BMS-986165) – oral – alopecia areata – TYK2 kinase inhibitor Finasteride/latanoprost/minoxidil (TH-07; Triple Hair) – topical – alopecia – combination drug/multiple mechanisms of action FOL-005 (osteopontin-derived peptide) – intradermal – alopecia – undefined mechanism of action GT-20029 (AR-PROTAC) – topical – alopecia – androgen receptor degradation enhancer KL-130008 – oral – alopecia areata – Janus kinase inhibitor Latanoprost (DLQ01; DLQ-01) – topical – androgenic alopecia – prostaglandin F receptor agonist (prostaglandin F2α analogue) NXC-736 – oral – alopecia areata – sphingosine 1 phosphate receptor antagonist Rezpegaldesleukin (Rezpeg; LY-3471851, NKTR-358) – unknown – alopecia areata – interleukin-2 conjugate/modulator RK-023 (nobiprostolan) – topical – alopecia, hypotrichosis – undefined mechanism of action (prostaglandin F2α analogue) Rosnilimab (ANB-030) – subcutaneous injection – alopecia areata – programmed cell death 1 receptor agonist Ruxolitinib (Jakafi, Jakavi, Opzelura; INCB-018424) – topical – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 2 inhibitor SIS-302-AA – unspecified – alopecia areata – undefined mechanism of action Suvomipic (PP405; PP-405; JXL069; JXL-069) – topical – alopecia – mitochondrial pyruvate carrier (MPC) inhibitor SYHX-1901 – oral – alopecia areata – Janus kinase inhibitor, Syk kinase inhibitor TDM-105795 (CU-40101) – topical – alopecia – thyroid hormone receptor agonist
Sources: en.wikipedia.org
Agouti-signaling protein is a protein that in humans is encoded by the ASIP gene. It is responsible for the distribution of melanin pigment in mammals. Agouti interacts with the melanocortin 1 receptor to determine whether the melanocyte (pigment cell) produces phaeomelanin (a red to yellow pigment), or eumelanin (a brown to black pigment). This interaction is responsible for making distinct light and dark bands in the hairs of animals such as the agouti, which the gene is named after. In other species such as horses, agouti signalling is responsible for determining which parts of the body will be red or black. Mice with wildtype agouti will be grey-brown, with each hair being partly yellow and partly black. Loss of function mutations in mice and other species cause black fur coloration, while mutations causing expression throughout the whole body in mice cause yellow fur and obesity. The agouti-signaling protein (ASIP) is a competitive antagonist with alpha-Melanocyte-stimulating hormone (α-MSH) to bind with melanocortin 1 receptor (MC1R) proteins. Activation by α-MSH causes production of the darker eumelanin, while activation by ASIP causes production of the redder phaeomelanin. This means where and while agouti is being expressed, the part of the hair that is growing will come out yellow rather than black.
=== Primary or secondary === The distinction between primary and secondary immunodeficiencies is based on whether the cause originates in the immune system itself or insufficiency of a supporting component or an external factor.
2 NaN3 → 2 Na + 3 N2 The same reaction occurs upon heating the salt to approximately 300 °C. The sodium that is formed is a potential hazard alone and, in automobile airbags, it is converted by reaction with other ingredients, such as potassium nitrate and silica. In the latter case, innocuous sodium silicates are generated. While sodium azide is still used in evacuation slides on modern aircraft, newer-generation automotive air bags contain less sensitive explosives such as nitroguanidine or guanidine nitrate.
Cytochrome c has been used to detect peroxide production in biological systems. As superoxide is produced, the number of oxidised cytochrome c3+ increases, and reduced cytochrome c2+ decreases. However, superoxide is often produced with nitric oxide. In the presence of nitric oxide, the reduction of cytochrome c3+ is inhibited. This leads to the oxidisation of cytochrome c2+ to cytochrome c3+ by peroxynitrous acid, an intermediate made through the reaction of nitric oxide and superoxide. Presence of peroxynitrite or H2O2 and nitrogen dioxide NO2 in the mitochondria can be lethal since they nitrate tyrosine residues of cytochrome c, which leads to disruption of cytochrome c's function as an electron carrier in the electron transport chain.
In bacteria, termination of RNA transcription can be rho-dependent or rho-independent. The former relies on the rho factor, which destabilizes the DNA-RNA heteroduplex and causes RNA release. The latter, also known as intrinsic termination, relies on a palindromic region of DNA. Transcribing the region causes the formation of a "hairpin" structure from the RNA transcription looping and binding upon itself. This hairpin structure is often rich in G-C base-pairs, making it more stable than the DNA-RNA hybrid itself. As a result, the 8 bp DNA-RNA hybrid in the transcription complex shifts to a 4 bp hybrid. These last 4 base pairs are weak A-U base pairs, and the entire RNA transcript will fall off the DNA. Transcription termination in eukaryotes is less well understood than in bacteria, but involves cleavage of the new transcript followed by template-independent addition of adenines at its new 3′ end, in a process called polyadenylation.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.